Frequency of positive family history among patients with axSpA in the ASAS, DESIR, ASAS-PerSpA and SPACE cohorts
| HLA-B27+ axSpA | HLA-B27− axSpA | No axSpA | |
| ASAS-PerSpA cohort | n=1609 | n=439 | Not available |
| Any positive family history* | 631 (39) | 149 (34) | – |
| Family history of axSpA | 518 (32) | 90 (21) | – |
| Family history of uveitis | 66 (4) | 10 (2) | – |
| Family history of psoriasis | 148 (9) | 57 (13) | – |
| Family history of IBD | 47 (3) | 27 (6) | – |
| Family history of ReA | 14 (1) | 3 (1) | – |
| ASAS cohort | n=254 | n=114 | n=226 |
| Any positive family history* | 74 (29) | 17 (15) | 44 (19) |
| Family history of axSpA | 61 (24) | 4 (4) | 22 (10) |
| Family history of uveitis | 4 (2) | – | 3 (1) |
| Family history of psoriasis | 12 (4) | 11 (10) | 13 (6) |
| Family history of IBD | 1 (1) | 2 (2) | 9 (4) |
| Family history of ReA | 3 (1) | 2 (2) | 3 (1) |
| DESIR cohort | n=410 | n=297 | Not available |
| Any positive family history* | 172 (42) | 101 (34) | – |
| Family history of axSpA | 111 (27) | 28 (9) | – |
| Family history of uveitis | 31 (8) | 1 (<1) | – |
| Family history of psoriasis | 75 (18) | 66 (22) | – |
| Family history of IBD | 17 (4) | 18 (6) | – |
| Family history of ReA | 2 (<1) | 5 (2) | – |
| SPACE cohort | n=265 | n=122 | n=421 |
| Any positive family history* | 130 (49) | 45 (37) | 181 (44) |
| Family history of axSpA | 76 (29) | 10 (8) | 81 (19) |
| Family history of uveitis | 24 (9) | 3 (2) | 22 (5) |
| Family history of psoriasis | 53 (20) | 33 (27) | 80 (19) |
| Family history of IBD | 14 (5) | 9 (7) | 40 (10) |
| Family history of ReA | 3 (1) | 1 (1) | 32 (8) |
Results are presented as n (%).
Significant results (p<0.05) are printed in bold.
*A positive family history of any of the SpA entities, that is, axSpA, uveitis, psoriasis, IBD or ReA.
ASAS, Assessment in SpondyloArthritis international Society; ASAS-PerSpA, ASAS peripheral involvement in Spondyloarthritis; axSpA, axial spondyloarthritis; DESIR, DEvenir des Spondyloarthropathies Indifférenciées Récentes; HLA-B27, human leucocyte antigen B27; IBD, inflammatory bowel disease; ReA, reactive arthritis; SpA, spondyloarthritis; SPACE, SPondyloArthritis Caught Early.